GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition

Hiromi Ito1*, Osamu Ichiyana1, Sei Naito1, Vladimir N. Bilim2, Yoshihiko Tomita2, Tomoyuki Kato1, Akira Nagaoka1 and Norihiko Tsuchiya1

Abstract

Background: The phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin 1 (mTORC1) signaling pathway is aberrantly activated in renal cell carcinoma (RCC). We previously demonstrated glycogen synthase kinase-3β (GSK-3β) positively regulated RCC proliferation. The aim of this study was to evaluate the role of GSK-3 in the PI3K/Akt/mTORC1 pathway and regulation of the downstream substrates, eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1), ribosomal protein S6 kinase (S6K), and ribosomal protein S6 (S6RP).

Methods: We used human RCC cell lines (ACHN, Caki1, and A498) and, as normal controls, human renal proximal tubular epithelial cell (HRPTEpC) and non-tumorous kidney tissues that were obtained surgically for treatment of RCC patients. Rapamycin-resistant ACHN (ACHN/RR) cells were generated with chronic exposure of ACHN to rapamycin ranging from 1nM finally to 1μM. Cell viability, cell cycling and direct interaction between GSK-3β and 4EBP1 were evaluated with MTS assay, flowcytometry and in vitro kinase assay with recombinant GSK-3β and 4EBP1 products, respectively. Protein expression and phosphorylation of molecules associated with the PI3K/Akt/mTORC1 pathway were examined by immunoblotting. Effects of drug combination were determined as the combination index with CompuSyn software.

Results: Overexpression and phosphorylation of 4EBP1 and S6RP together with GSK-3 activation were observed in RCC cell lines, but not in human normal kidney cells and tissues. Cell proliferation, p4EBP1 and pS6RP were strongly suppressed by GSK-3 inhibition. Rapamycin-resistant ACHN (ACHN/RR) cells were generated with chronic exposure of ACHN to rapamycin ranging from 1nM finally to 1μM. Cell viability, cell cycling and direct interaction between GSK-3β and 4EBP1 were evaluated with MTS assay, flowcytometry and in vitro kinase assay with recombinant GSK-3β and 4EBP1 products, respectively. Protein expression and phosphorylation of molecules associated with the PI3K/Akt/mTORC1 pathway were examined by immunoblotting. Effects of drug combination were determined as the combination index with CompuSyn software.

Conclusions: GSK-3β could directly phosphorylate 4EBP1 and activate the mTORC1 downstream signaling cascades to enhance protein biosynthesis and cell proliferation in RCC cell lines independent of rapamycin sensitivity. The direct GSK-3β/4EBP1 pathway might be an important subcellular mechanism as an inherent equipment for RCC cells to acquire clinical chemoresistance to mTORC1 inhibitors.

Keywords: Akt, GSK-3β, mTORC1, 4EBP1, Renal cell carcinoma, Rapamycin resistance, Combination index

* Correspondence: ito.hiromi@med.id.yamagata-u.ac.jp
1Department of Urology, Yamagata University Faculty of Medicine, 2-2-2 Iida-Nishi, Yamagata 990-9585, Japan
Full list of author information is available at the end of the article

© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Renal cell carcinoma (RCC) is the most frequent form of kidney cancer, accounting for up to 85 % of all cases [1]. Approximately 25–30 % of patients have metastatic RCC (mRCC) at initial diagnosis [1]. The survival of patients with mRCC has recently prolonged drastically, owing to the development of novel targeted drugs [2]. In most cases, tyrosine kinase inhibitors (TKIs) targeting vascular endothelial growth factor are preferably administered as the first-line drugs for treating mRCC [2, 3]. Two rapprochements that inhibit mammalian target of rapamycin complex 1 (mTORC1), everolimus and temsirolimus, have also been introduced in clinical practice for treating patients with mRCC [2, 3]. However, it is still extremely rare to achieve a complete response with these drugs [2, 4]. Patients with mRCC succumb to the disease once they lapse into refractory status. Thus, further improvement of the therapeutic modality is warranted.

The phosphoinositide 3-kinase (PI3K)/Akt/mTORC1 signaling pathway is an important regulator of cell growth, cell cycling, cell proliferation, metabolism, apoptosis, autophagy, and angiogenesis [5, 6], and is frequently activated in a wide variety of cancers, including RCC [5, 7]. mTORC1 controls these numerous cellular functions mainly via the best-characterized substrates ribosomal protein S6 kinase (S6K) and eukaryotic translation initiation factor 4E (eIF4E)-binding protein 1 (4EBP1) [5, 6]. S6K and 4EBP1 collaborate to play a role in 5’ cap-dependent mRNA translation [6]. S6K stimulates protein synthesis and cell growth, whereas 4EBP1 plays a predominant role in cell proliferation [8]. Experiments involving inhibition of mTORC1 with rapamycin have revealed the differential regulation between its two downstream substrates, S6K and 4EBP1, in a cell type-specific manner [9]. Furthermore, recent reports have suggested that 4EBP1 phosphorylation is directly correlated with the malignancy and severity of various tumors, including RCC [10, 11]. Although mTORC1 seems to be the chief phosphorylation pathway of 4EBP1, other unidentified kinases and biochemical mechanisms are also involved such as cyclin-dependent kinase 1, ataxia-telangiectasia mutated/p53, RAS/extracellular signal-regulated kinase1/2 and other collateral signaling pathways [10, 12]. This is because multiple phosphorylation sites in 4EBP1 can be partially insensitive to rapamycin [10, 12–15]. It is well-known that the mTOR pathway is also an important regulator of hypoxia inducible factor, an essential driver of clear cell RCC due to disruption of the von Hippel Lindau (VHL) tumor suppressor gene, the somatic mutation of which is the most frequent genetic alteration observed in RCC [16].

Glycogen synthase kinase-3 (GSK-3) is a ubiquitously expressed Ser/Thr kinase that regulates cellular function via several mechanisms, including Wnt/β-catenin and Hedgehog signal transduction, protein synthesis, glycogen metabolism, mitosis, and apoptosis [17–19]. GSK-3 has two closely related isoforms, GSK-3α and GSK-3β, which exhibit 97 % sequence identity within their catalytic domains [17, 19]. GSK-3 can act as a tumor suppressor or it can promote cell proliferation in different types of cancers [17–19]. We previously demonstrated that GSK-3β positively regulates the proliferation, survival, and anti-apoptosis mechanisms of cancer cells through decreased expression of the nuclear factor-kappa B target genes BCL-2 and X-linked inhibitor of apoptosis protein (XIAP) [18, 20], and that nuclear accumulation of GSK-3β could be a novel biomarker of bladder cancer [18] and RCC [20]. Furthermore, we demonstrated that nuclear overexpression of GSK-3β and tumor proliferation in RCC are negatively regulated by miR-199, the only microRNA known to target GSK-3β [21]. Moreover, pharmacological inhibition of GSK-3 was found to potentiate the anti-tumorous efficacy of sorafenib, a TKI that is used for systemic therapy of mRCC [22].

In the present study, we investigated direct relationships between GSK-3β and 4EBP1 using human RCC cell lines and a normal renal tubular epithelial cell line, and normal renal tissues obtained from RCC patients who had surgical resection, in order to study the role of GSK-3 in the Akt/mTORC1/4EBP1 pathway in RCC.

Methods
Cell culture and reagents
The RCC cell lines ACHN, Caki1, and A498 were obtained from American Type Culture Collection (Manassas, VA, USA). ACHN is derived from pleural effusion in metastatic RCC having wild type of VHL [23, 24]. Caki1 and A498 cells come from clear cell RCC with VHL wild type [23, 25], and clear cell RCC with VHL mutation (426_429delT-GAC) [25], respectively. Cells were cultured in RPMI medium supplemented with 50 µg/mL of kanamycin and 10 % fetal bovine serum in an incubator at 5 % CO₂ and 37 °C. Human renal proximal tubular epithelial cell (HRPTEpC) was obtained from Cell applications Inc (San Diego, CA, USA). Cells were cultured in RenalEpi cell growth medium with growth supplements in an incubator at 5 % CO₂ and 37 °C. AR-A014418 was purchased from Calbiochem (San Diego, CA, USA). Two other GSK-3 inhibitors, SB-216763 and TDZD8, were obtained from Cayman Chemicals (Ann Arbor, MI, USA) and Sigma-Aldrich (Tokyo, Japan), respectively. Rapamycin and everolimus were obtained from Selleck Chemicals (Houston, TX, USA), LY294002 was from Wako Pure Chemical Industries (Tokyo, Japan), recombinant GSK-3β was purchased from New England Biolabs (NEB) Japan (Tokyo, Japan), and
recombinant GST-4EBP1 was obtained from Sigma-Aldrich Japan.

**Induction of rapamycin-resistant renal cancer cell lines**
The RCC cell line ACHN was cultured in progressively increasing dose of rapamycin until sustained growth, used concentration ranging from 1nM finally to 1 μM (for approximately 4 months). Before use the rapamycin-resistant cells to investigate drug effects, the cells were cultured in RPMI medium without rapamycin for five passages.

**siRNA transfection**
For GSK-3β or GSK-3α silencing, ACHN cells were transfected with specific human siRNAs against GSK3β (25 μM or 50 μM) or GSK3α (50 μM) by using Lipofectamine RNAiMAX (Invitrogen, Thermo Fisher Scientific Inc. Yokohama, Japan) according to the manufacturer’s recommendations. Targeting sequences of siRNA are as follows: GSK-3β; 5′-GGACAAAGAGAUUUAGAAtt-3′ (Applied BioSystems, Thermo Fisher Scientific Inc.), GSK-3α (siE523); 5′-GUCCUCACAAGCUUACUt-3′; GSK-3α (siE524); 5′-GUCUUAGUUUCCACAGUAAtt-3′ (TaKaRa Bio Inc., Shiga, Japan). Non-specific control siRNA (Applied BioSystems) was used as negative control.

**Preparation of normal human kidney tissues**
Fresh frozen tissue samples obtained from three patients with RCC who underwent nephrectomy at Yamagata University Hospital were used in the present study. The samples cut from the non-tumorous renal parenchyma away from RCC areas were freshly frozen and maintained at −80 °C until the experiments. The study was approved by the Ethics Committee of Yamagata University Faculty of Medicine (approval no. 55, 2015), and all patients signed an informed consent form.

**Immunoblot analysis**
Immunoblot analysis was performed as described previously [22], using SuperSignal West Pico Substrate (Pierce, Rockford, IL, USA) and Western Blot Hyper HRP Substrate (Takara Bio Inc) according to the manufacturers’ instructions. The images were analyzed using UN-SCAN-Itgel Automated Digitizing System software (Version 5.1 for Windows, Silk Scientific Inc., Orem, UT, USA). The antibodies to the following chemicals were used: 4EBP1, p4EBP1 (The70, Thr37/46, and Ser65), S6K, pS6K (Ser371), ribosomal protein S6 (S6RP), pS6RP (Ser240/244), glycogen synthase (GS), pGS (Ser641), Akt, pAkt (Ser473), GSK-3β and GSK-3α. These antibodies were obtained from Cell Signaling Technology Japan (Osaka, Japan). β-actin was used as a loading control and anti-β-actin was obtained from Abcam Inc. (Cambridge, MA, USA).

**Protein kinase assays**
Kinase assays were performed for 30 min at 30 °C with 0.5 μL of recombinant GSK-3β (NEB) and 0.5 μg of recombinant GST-4EBP1 in kinase buffer (50 mM Tris–HCl, 50 mM NaCl, 5 mM dithiothreitol, 1 mM ethylenediaminetetraacetic acid (EDTA), 50 % glycerol, and 0.03 % Brij 35, pH 7.5) containing 500 μM ATP in the presence and absence of 25 μM AR-A014418 or SB-216763. The reaction products were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and immunoblot analysis was performed.

**Cell proliferation assay**
ACHN, Caki1, and A498 RCC cells were cultured at 24, 48, and 72 h in the presence and absence of an mTORC1 or GSK-3 inhibitor. The cell viability was estimated using CellTiter 96 Aqueous One Solution Cell Proliferation Assay (Promega, Madison, WI, USA) as described previously [21]. Values of the half maximal inhibitory concentration (IC₅₀) were calculated by fitting concentration-response curves to a four-parameter logistic sigmoidal function model using R package ‘drc’ (http://www.bioassay.dk). Synergistic, additive, or antagonistic effects of AR-A014418 and rapamycin combination treatment were determined based on the theorem of Chou and Talalay [26], using a free software CompuSyn (www.combosyn.com). The dose–effect relationships for single agents and their combinations were analyzed, and the combination index (CI) values were calculated for each dose and the corresponding effect level, designated as the fraction affected (Fa) meaning the inhibited fraction of cell proliferation after drug administration. For graphical presentation of drug interaction, a Fa-CI plot was constructed by simulating CI values with CompuSym over a range of Fa levels from 0.05 to 0.97. The CI values provide a quantitative definition for an additive effect (CI = 1), synergism (CI < 1), and antagonism (CI > 1) in drug combinations.

**Cell cycle analysis**
After treatment with AR-A014418 or rapamycin, ACHN cells were harvested with trypsin-EDTA, centrifuged into a pellet, and rinsed with phosphate-buffered saline (PBS). Then, 80 % ethanol was added, and the cells were incubated on ice for 1 h. The cells were washed with PBS, re-suspended in PBS containing 20 μg/mL RNase and 50 μg/mL propidium iodide (Sigma-Aldrich Japan), and incubated at 37 °C for 1 h. The cells were analyzed using the FACScanII flow cytometry (Becton-Dickinson, San Diego, CA, USA).
Statistical analysis
Continuous variables are presented as the mean ± standard deviation (SD) for bar-charts and as the mean ± standard error (SE) for concentration-response plots. They were statistically analyzed using analysis of variance (ANOVA) and, if necessary, a post-hoc Bonferroni test for multiple comparisons. P < 0.05 was considered statistically significant. All analyses were performed using R statistical software version 3.1.0 (http://cran.r-project.org/).

Results
GSK-3 inhibition shows different modes of anti-proliferative action in ACHN cells
We investigated cell proliferation in ACHN RCC cells treated with inhibitors of mTORC1 or GSK-3. Treatment of rapamycin and its derivative everolimus, both of which are inhibitors of mTORC1, reduced cell viability, and the ACHN cell viability leveled off when the concentrations of the rapalogues were higher than 10 nM (Fig. 1a and b). By contrast, AR-A014418 and SB-216763, both of which are ATP-competitive and small-molecule inhibitors of GSK-3 [27, 28], decreased cell viability in a concentration-dependent manner (Fig. 1c and d). We further investigated the cell proliferation of human RCC cell lines (ACHN, Caki1 and A498) using in detail-concentration of AR-A014418 and rapamycin (Additional file 1: Figure S1). Generally, all the three cell lines were less sensitive to rapamycin than AR-A014418, not having reached 50% inhibition of cell viability from baseline even at high doses of rapamycin (1000 nM), whereas the cell lines showed a dose-dependent decrease in proliferation with IC50 between 27 and 45 μM treated with AR-A014418 (Additional file 1: Figure S1). Rapamycin caused G0/G1 arrest in ACHN cells without inducing apoptosis (Fig. 1e). Similar to our previous study [14], AR-A014418 induced apoptosis in conjunction with the increase in the subG1 phase at 48 h (Fig. 1f). Using immunoblotting, we confirmed that GSK-3 inhibition with AR-A014418 induced dose- and time-dependent apoptosis, as measured by poly ADP ribose polymerase (PARP) cleavage and reduction of XIAP (data not shown). In contrast, AR-A014418 also reduced the G0/G1 phase at 24 h independently of the increase in the subG1 phase, implicating the possibility of anti-mitotic action that is independent of apoptosis (Fig. 1f).

Pharmacological and genetic inhibition of GSK-3 prevents the downstream phosphorylation of mTORC1
To examine the role of GSK-3 in the mTORC1 downstream signaling pathway and its effects on cell proliferation, we treated ACHN, Caki1, and A498 human RCC cells, with AR-A014418, an ATP-competitive and small-molecule inhibitor of GSK-3 [27], and examined its
effects on the phosphorylation of 4EBP1, S6K, and S6RP (Fig. 2a). Immunoblot analysis showed that p4EBP1 at Thr70, Thr37/46, and Ser65 were suppressed with treatment of AR-A014418 in all the three cell lines. In parallel, AR-A014418 simultaneously inhibited the phosphorylation of S6K at Ser37 and its downstream substrate pS6RP at Ser240/244. Treatment with two other GSK-3 inhibitors, SB-216763 (ATP-competitive) [28] and TDZD8 (ATP-non-competitive) [29], also reduced p4EBP1 and pS6RP levels in ACHN cells (Fig. 2b). GSK-3 has a primary role in the phosphorylation of glycogen synthase (GS), and it is known to directly phosphorylate S6K at Ser371 in vitro. [30] Here, we found that AR-A014418 induced dose- and time-dependent inhibition of GSK-3 activity, as measured by pGS at Ser641 and pS6K at Ser371 levels (Fig. 2a).

Next, to determine which of two GSK-3 isoforms, GSK-3α and GSK-3β, phosphorylates 4EBP1, we examined p4EBP1 status in stable GSK-3α and GSK-3β knockdown cells with siRNAs, respectively (Fig. 2c). As expected, 4EBP1 phosphorylation at Thr70, Thr37/46 and Ser65 in siGSK-3-β-transfected ACHN cells decreased than negative controls. However, siGSK-3-α knockdown presented with inconsistent outcome, no changes and reduction in p4EBP1 for each of two specific siGSK-3-α transfected, respectively (Fig. 2c).

Compared with the human renal proximal tubular epithelial cells (HRPTEpC) and the normal renal parenchymas, the mTORC1 downstream pathway was strongly activated in the RCC cell lines (Fig. 2d). These results indicate that GSK-3β, rather than GSK-3-α, is required to maintain 4EBP1, S6K, and S6RP phosphorylation in RCC cells.

GSK-3 regulates 4EBP1 and S6RP phosphorylation differently from PI3K/Akt/mTORC1 pathway
To investigate the relationship GSK-3 and mTORC1 pathway further, we next examined the effect of AR-A014418 and rapamycin on phosphorylation of 4EBP1 and S6RP, the downstream signaling targets of mTORC1. The phosphorylation levels of 4EBP1 and S6RP in ACHN cells decreased rapidly at 30 min after exposure to AR-A014418, and the phosphorylation remained suppressed through 48 h (Fig. 3a, left). In contrast, rapamycin temporarily suppressed 4EBP1 phosphorylation at Thr70 from 2 to 12 h and at Thr37/46 and Ser65 from 4 to 12 h, but did not prevent phosphorylation at Thr37/46, Thr70 and Ser65 at 24 and 48 h. S6RP phosphorylation was partially suppressed from 0.5 to 12 h, and were finally restored at 24 and 48 h as well as p4EBP1 (Fig. 3a, right). Similar to rapamycin, LY294002, a PI3K/Akt/mTORC1 inhibitor, moderately attenuated p4EBP1 at Thr70 and Ser65 without apparent changes at Thr37/46 phosphorylation. As expected, LY294002 also inhibited pAkt and pS6RP simultaneously (Fig. 3b). To our investigation, the effect of AR-A014418
Fig. 1 (See legend on next page.)
on Akt phosphorylation at Ser473 varied according to the concentrations and RCC cell lines (Additional file 2: Figure S2). However, p4EBP1 commonly decreased in ACHN, Caki1, and A498 cells following AR-A014418 treatment (Fig. 3a and Additional file 2: Figure S2).

These results support that GSK-3 regulates the phosphorylation of 4EBP1 directly and S6K differentially in a manner independent of the PI3K/Akt/mTORC1 pathway. In addition, it reflects that 4EBP1 would take phosphorylation differentially at Thr70, Thr37/46 and Ser65.

GSK-3β could directly phosphorylate 4EBP1

We performed an in vitro kinase assay using recombinant proteins of GSK-3β and 4EBP1 (Fig. 4). Recombinant GSK-3β phosphorylated recombinant 4EBP1 at Thr70, Thr37/46, and Ser65. AR-A014418 and SB-216763 blocked the recombinant GSK-3β mediated phosphorylation of recombinant 4EBP1. These results suggest that GSK-3β could participate in the direct phosphorylation of 4EBP1 at Thr70, Thr37/46, and Ser65, as reported for S6K [30].
Biphasic response to drug combination of GSK-3 and mTORC1 inhibitors in a concentration-dependent fashion

In ACHN cells, we investigated cell proliferation with single agents and a combination of GSK-3 inhibitor (AR-A014418) and mTORC1 inhibitor (rapamycin) using the MTS assay. Different concentration in the combination was kept at a constant dilution ratio of 25,000 : 1. The dilution ratio was determined on IC_{50} values from concentration-response relation in MTS assay at 72 h for the single agents (Fig. 5a) [26]. The combination effects were determined as the combination index with CompuSyn software (Fig. 5b) [26]. The combination effects were additive at lower concentrations, but more antagonistic at higher concentrations.

**GSK-3 regulates cell proliferation and p4EBP1 independently of chemoresistance to rapamycin**

To confirm that GSK-3 regulates cell proliferation and 4EBP1 phosphorylation independently of PI3K/Akt/mTORC1 pathway, we furthermore investigated inhibitory effects of AR-A014418 in rapamycin-resistant ACHN (ACHN/RR) cells that were generated through culturing ACHN parental (ACHN/P) cells in progressively higher concentrations of rapamycin from 1nM
finally to 1 μM. As shown in Fig. 6a, ACHN/P cells were sensitive to rapamycin in proliferation, but ACHN/RR cells presented with rapamycin-resistance. In contrast, AR-A014418 suppressed greatly ACHN/P and ACHN/RR proliferation in concentration-dependent manner. Notably, the concentration-response relation for AR-A014418 did not differ from ACHN/P and ACHN/RR cells (Fig. 6b). In ACHN/RR cells, AR-A014418 remarkably inhibited p4EBP1 and pS6RP rapidly and the inhibition had continued constantly even at 48 h. However, phosphorylations of 4EBP1 and S6RP in ACHN/RR cells were suppressed only mildly and transiently by rapamycin. The phosphorylations almost recovered to the baseline in 24 h (Fig. 6c). The findings indicate that GSK-3 inhibition can sufficiently decrease the activities of mTORC1 downstream cascades and overcome rapamycin-resistance in RCC cells.

**Discussion**

Consistent with previous reports [30, 31], in the present study, we demonstrate that GSK-3β directly phosphorylates 4EBP1 independent of rapamycin sensitivity to mTORC1 and continuously activates 4EBP1 and S6K, the mTORC1 downstream substrates to drive cell proliferation in RCC cell lines. The present findings would also indicate that the direct GSK-3β/4EBP1 pathway is an important subcellular mechanism as an inherent equipment for RCC cells to acquire clinical chemoresistance to mTORC1 inhibitors. Although rapamycin increased the G0/G1 phase in cell cycle and suppressed cell proliferation, the inhibitory effects of rapamycin on the mTORC1 downstream pathway were only transient leading to gradual return of p4EBP1 and pS6RP to the baseline level. When the present results extrapolated into clinical setting, it could be easy for us to understand limited efficacy of mTORC1 inhibition on size reduction and progression of RCC [2, 3]. Our data suggest that GSK-3 inhibition could be a promising strategy for the treatment of mRCC.

GSK-3 in solid cancers have two opposite functions in different types of tumor cells, a suppressor (e.g., some skin and breast cancers) or promoter (e.g., colon, liver, ovarian and pancreatic tumors) [17–19, 32]. However, the underlying mechanisms to regulate the differentiation between the opposite roles of GSK-3 remain unsolved [32]. To date, we have reported that GSK-3β is highly expressed in tumor nuclei of RCC [21]. In human...
RCC specimens, aberrant GSK-3β overexpression that is negatively regulated by miR-199 [21] was observed in 68 out of 74 (92 %) cases, suggesting clinical relevance of RCC biology [20]. Using RCC cell lines, we have revealed that inhibition of GSK-3 results in decreased expression of NF-κB target genes Bcl-2 and XIAP leading to a subsequent increase in RCC apoptosis and the anti-tumor effect of sorafenib, TKI available for treatment of mRCC in clinical practice [20, 22]. According to a recent review [32], possible differences in apoptotic, Wnt/β-catenin, and NF-κB signaling pathways among various types of cancer may be related to the opposite effects of GSK-3 on tumor proliferation.

Drug combination of AR-A014418 and rapamycin in MTS assay for ACHN proliferation presented with additivity at lower concentrations, but antagonism at higher concentrations. The biphasic aspect, including the transition from additive to antagonistic, with increasing drug concentration indicated the presence of at least two regulatory pathways from GSK-3 to 4EBP1. The additive effect is considered to reflect a direct pathway independent of the PI3K/Akt/mTORC1 cascade. The antagonism at higher concentrations could possibly be competitive inhibition because GSK-3 and mTORC1 in combination share 4EBP1 and S6K as target substrates (Figs. 2, 3 and 6c).

4EBP1 plays an important role in cell proliferation by selectively translating mRNAs that encode various proteins promoting cell cycle and proliferation [8]. Phosphorylation, mainly at sites Thr37, Thr46, Ser65, and Thr70, causes 4EBP1 to dissociate from eIF4E, allowing for cap-dependent translation [33, 34]. It is widely accepted that mTORC1 is a main regulator of 4EBP1 to keep cellular homeostasis [35]. However, as shown in Fig. 2d, 4EBP1 and S6RP expression and phosphorylation aberrantly increased in RCC cells but not in normal kidney tissues and a renal tubular cell line, suggesting that GSK-3 as well as mTORC1 could be involved in the activation of mTORC1 downstream pathway in RCC. Moreover, rapamycin and LY294002 only partially inhibited the phosphorylation of 4EBP1 (Fig. 3a and b) [15]. Not only pharmacological but also genetic inhibition of GSK-3β with specific siRNAs sufficiently decreased phosphorylation of mTORC1 downstream substrates in RCC cell lines (Figs. 1 and 2). Therefore, we here provide the evidence that GSK-3β can directly phosphorylate 4EBP1 at Thr37/46, Thr70, and Ser65, possibly in sequential order (Fig. 4). In particular, p4EBP1 was rapidly inhibited following AR-A014418 treatment at 30 min in ACHN cells (Fig. 3a) and within 1 h in acquired rapamycin-resistant ACHN cells (Fig. 6c), supporting the direct involvement of GSK-3β in 4EBP1 phosphorylation in RCC cells.

Approximately 100 substrates of GSK-3 have been identified to date [17, 19]. Recently, several researchers reported about relationships between GSK-3β and Akt/mTORC1/4EBP1 pathway [31, 36–38]. However, to our knowledge, only two papers have referred to direct interaction of GSK-3β and 4EBP1 currently [31, 38]. According to Shin et al. [31], GSK-3β directly phosphorylates 4EBP1 at Thr37/46 and inactivates 4EBP1 activity in breast cancer and normal cell lines, thereby increasing eIF4E-dependent protein synthesis and regulating cell proliferation. In addition, they showed that GSK-3β
significantly reduced in vivo the size of tumor injected subcutaneously in a mouse xenograft model [31]. Many GSK-3β substrates have the motif Ser/Thr-Pro-X-X-Ser/Thr [39]. The binding affinity of GSK-3β to a substrate is enhanced if the substrate receives prior phosphorylation at the second Ser/Thr [19]. 4EBP1 reportedly has seven phosphorylation sites (Thr37/46, Ser65, Thr70, Ser83, Ser101, and Ser112) [14, 39]. Comparison of the 4EBP1 sequence with those of known GSK-3β substrates showed that the best-matched sequences in 4EBP1 for phosphorylation by GSK-3β are Thr-Pro-Gly-Gly-Thr for both Thr37 and Thr46 as the first Ser/Thr residues [40]. Phosphorylation of 4EBP1 at Thr37/46 by GSK-3β requires pre-phosphorylation at priming sites (Thr41/50) [31]. However, GSK-3 does not necessarily require a primed substrate [17, 19, 41]. The residues other than Thr37/46, Thr70, and Ser65 in 4EBP1 might be also targeted by GSK-3β. In the present study, we demonstrated that recombinant GSK-3β phosphorylated an unprimed recombinant 4EBP1 at Thr37/46. It is possible that phosphorylation of Thr41/50 also is regulated by GSK-3β itself. There are no priming phosphorylation sites at Thr70 and Ser65 of 4EBP1 (Thr70, Pro-Pro-Arg-Asp, Ser65, Pro-Val-Thr-Lys). The phosphorylation of 4EBP1 appears to occur in a hierarchical manner, as follows [13, 14]: Thr37/46 are phosphorylated at baseline, and this is further enhanced by insulin production [13, 14]. Thr37/46 phosphorylation is followed by phosphorylation of Thr70, followed by phosphorylation of Ser65 as the last step [13]. Phosphorylation of Thr70 seems to play the most important role in releasing 4EBP1 from elf4E [14]. The fact that the phosphorylation levels of recombinant unprimed 4EBP1 increased in the order of Thr37/46, Thr70, and Ser65 likely reflects this hierarchical phosphorylation process (Fig. 4). As shown in Fig. 3, LY294002 and rapamycin exhibited apparently no and slightly inhibitory action on Thr37/46 phosphorylation in 4EBP1, respectively, leading to the notion that Thr37/46 residue may be the main target of GSK-3 in case of 4EBP1 phosphorylation [31]. Abnormal overexpression of GSK-3 is observed in cancers which are resistant to chemo-, radio- and targeted therapy [32]. Targeting GSK-3 could improve cancer therapy and overcome therapeutic resistance [32].

The mechanism by which GSK-3 inhibition results in fluctuations of pAkt at Ser437 over time is currently unclear (Additional file 2: Figure S2). One potential mechanism is that at the early phase, inhibition of GSK-3β by AR-A014418 results in the hypo-phosphorylation of Ser1235 of rictor, a component of mTORC2 that activates Akt via pSer437 [42]. Another possibility is that S6K could participate in negative feedback regulation to affect the phosphorylation of rictor at Thr1135 through the insulin receptor substrate 1/PI3K axis [6, 43]. A third potential mechanism could involve apoptosis-induced protein degradation and the consequent reduction of pAkt [5, 6]. Although GSK-3 inhibition appears to induce variable reactions of pAkt at Ser473 with unknown mechanisms, it consistently suppressed 4EBP1 and mTORC1 downstream signaling in RCC cells in the present study. In their report, Armengol et al. [10] stated that 4EBP1 would act as a key molecular funnel factor in carcinogenesis of various types of human cancers, regardless of the upstream oncogenic alterations. The results of the present study on RCC cells seem to support this hypothesis.

Conclusions

GSK-3β could directly phosphorylate 4EBP1 and activate the mTORC1 downstream signaling cascades to enhance protein biosynthesis and cell proliferation in RCC cell lines independent of rapamycin sensitivity. The direct GSK-3β/4EBP1 pathway, not associated with the PI3K/Akt/mTORC1 pathway, would be an important subcellular intrinsic mechanism for RCC cells to resist mTORC1 inhibition, possibly leading to potential therapeutic limitations in systemic treatment for mRCC patients with rapalogues.

Additional files

Additional file 1: Figure S1. Differences in suppressive effects of mTORC1 and GSK-3 inhibitors on cell proliferation. Relative cell viability was measured by an MTS assay in ACHN, Caki1 and A498 cells treated with rapamycin (A), and AR-A014418 (B) at the indicated concentrations at 72 h. A498 cells, highly insensitive to rapamycin, did not reach maximal inhibitory effect even at 10 μM rapamycin, with IC₅₀ not assessable (NA). Data are the mean ± SE from six replicates of each cell line. In (A) and (B), significant interaction between cell lines and drug concentrations was statistically detected with two-way ANOVA (p < 0.05). As for the simple main effect, the difference in cell lines (ACHN, Caki1 or A498) was statistically significant for rapamycin (one-way ANOVA, p < 0.05, Bonferroni test); p < 0.05 for ACHN vs. Caki1 and A498 and not significant for AR-A014418 (one-way ANOVA; p = 0.47). (PPTX 60 kb)

Additional file 2: Figure S2. Different effects of GSK-3 inhibition on Akt and 4EBP1 phosphorylation. (A) ACHN cells were treated with AR-A014418 (25 μM) or rapamycin (100 nM) for the indicated times. Cells were lysed and analyzed for pAkt by immunoblotting. (B) Caki1 and A498 cells were treated with AR-A014418 at 25 μM or 50 μM for 24 h or 48 h, respectively. Immunoblotting was performed after cell lysis. In (A) and (B), Data are representative of at least three separate immunoblot analyses. (PPTX 107 kb)

Abbreviations

4EBP1, eukaryotic translation initiation factor 4E (elf4E)-binding protein 1; CI, combination index; elf4E, eukaryotic translation initiation factor 4E; GS, glycogen synthase; GSK-3, glycogen synthase kinase-3; GST, glutathione S-transferase; mRCC, metastatic renal cell carcinoma; mTOR, mammalian target of rapamycin; mTORC, mammalian target of rapamycin (mTOR) complex; PI3K, phosphoinositide 3-kinase; RCC, renal cell carcinoma; S6K, ribosomal protein S6 kinase; S6RP, ribosomal protein S6; TKI, tyrosine kinase inhibitor; VHL, von Hippel Lindau; XIAP, X-linked inhibitor of apoptosis protein
Acknowledgements
We would like to thank Editage (www.editage.jp) for the English language editing.

Funding
This work was supported by Grants-in-Aid for Scientific Research from the Japan Society for Promotion of Science (15 K10573, 16 K10993 and 16 K20123).

Availability of data and material
Data will not be shared at the moment since these data are used for further publications.

Authors’ contributions
HI, OI, BV and SN participated in the design of the present study. HI, SN and OI drafted the manuscript and figures. HI participated in all experiments. BV and SN performed western blotting in part. TY, TK, AN and NT conceived the study, participated in its design and coordination, and helped with drafting the manuscript. All authors have read and approved the final manuscript.

Authors’ information
*Department of Urology, Yamagata University Faculty of Medicine, Yamagata 990-9585, Japan. †Division of Urology, Department of Regenerative and Transplant Medicine, Niigata Graduate School of Medical and Dental Sciences, Niigata 951-8510, Japan. ‡Department of Urology, Department of Regenerative and Transplant Medicine, Niigata Graduate School of Medical and Dental Sciences, 1-757, Asahimachi-dori, Chuo-ku, Niigata 951-8510, Japan. HI is a basic scientist. OI and TK are lecturers. SN is an associate professor. AN is an associate professor. NT is a professor and chairman.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
The present study contained results from human RCC samples which obtained surgically from anonymous patients. The Ethics Committee of Yamagata University Faculty of Medicine has approved the publication of this research outcome in the framework of anonymity (approval no. 55, 2015).

Ethics approval and consent to participate
This study was approved by the Ethics Committee of Yamagata University Faculty of Medicine (approval no. 55, 2015) and all patients signed an informed consent form.

Author details
*Department of Urology, Yamagata University Faculty of Medicine, 2-2-2 Iida-Nishi, Yamagata 990-9585, Japan. †Division of Urology, Department of Regenerative and Transplant Medicine, Niigata Graduate School of Medical and Dental Sciences, 1-757, Asahimachi-dori, Chuo-ku, Niigata 951-8510, Japan.

Received: 2 December 2015 Accepted: 27 June 2016

Published online: 07 July 2016

References
1. Pal SK, Quinn DI. Differentiating mTOR inhibitors in renal cell carcinoma. Cancer Treat Rev. 2013;39(7):709–19.
2. Coppen C, Kollmannsberger C, Le L, Porzolt F, Wilt TJ. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials. BJU Int. 2011;108(10):1556–63.
3. Ljungberg B, Benndorf K, Rex A, Canfield S, Dabestani S, Giles RH, et al. Guidelines on Renal Cell Carcinoma. In. Edited by Ljungberg B. European Association of Urology. http://uroweb.org/guideline/renal-cell-carcinoma/#7.
4. Albiger L, Oudard S, Negrier S, Caty A, Gravis G, Joly F, et al. Complete remission with tyrosine kinase inhibitors in renal cell carcinoma. J Clin Oncol. 2012;30(3):482–7.
5. Fung C, Figlin RA. Phosphatidylinositol-3-kinase/Akt signalling pathway and kidney cancer, and the therapeutic potential of phosphatidylinositol-3-kinase/Akt inhibitors. J Urol. 2009;182(6):2569–77.
6. Magnuson B, Ekm B, Fingar DC. Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks. Biochem J. 2012; 441(1):1–21.
7. Choo AY, Blenis J. Not all substrates are treated equally: implications for mTOR, rapamycin-resistance and cancer therapy. Cell Cycle. 2009;8(4):567–72.
8. Dowling RJ, Topisirovic I, Alain T, Bidinosti M, Fonseca BD, Petroulakis E, et al. mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science. 2010;328(5982):1172–6.
9. Choo AY, Yoon SQ, Kim SG, Roux PP, Blenis J. Rapamycin differentially inhibits 56ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci U S A. 2008;105(45):17414–9.
10. Armengol G, Rojo F, Castellvi J, Iigiesa C, Cuarteras M, Pons B, et al. 4E-binding protein 1: a key molecular “funnel factor” in human cancer with clinical implications. Cancer Res. 2007;67(16):7551–5.
11. Nishikawa M, Miyake H, Harada K, Fujisawa M. Expression level of phosphorylated-4E-binding protein 1 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with mammalian target of rapamycin inhibitors. Med Oncol. 2014;31(1):792.
12. She QB, Hallivick E, Ye Q, Zhen W, Shirasawa S, Sasaki T, et al. 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signalling pathways that integrates their function in tumors. Cancer Cell. 2010;18(1):39–51.
13. Gingras AC, Raught B, Gygi SP, Nizidiekwa A, Miron M, Burley SK, et al. Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev. 2001;15(21):2852–64.
14. Proud CG. mTOR-mediated regulation of translation factors by amino acids. Biochem Biophys Res Commun. 2004;313(2):429–36.
15. Wang X, Beugnet A, Murakami M, Yamanaka S, Proud CG. Distinct signaling events downstream of mTOR cooperate to mediate the effects of amino acids and insulin on initiation factor 4E-binding proteins. Mol Cell Biol. 2005;25(7):2558–72.
16. Sato Y, Yoshizato T, Shiraih T, Maewa S, Okuno Y, Yamura T, et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet. 2013;45(8):860–7.
17. Beurel E, Greico SF, Jope RS. Glycogen synthase kinase-3 (GSK3); regulation, actions, and diseases. Pharmacol Ther. 2015;148:114–31.
18. Naito S, Bilim V, Yuuki K, Ugoikov A, Motoyama T, Nagaoka A, et al. Glycogen synthase kinase-3beta: a prognostic marker and a potential therapeutic target in human bladder cancer. Clin Cancer Res. 2010;16(21):5124–32.
19. Donle BW, Woodgett JR. GSK3: tricks of the trade for a multi-tasking kinase. J Cell Sci. 2003;116(Pt 7):7117–5.
20. Bilim V, Ugoikov A, Yuuki K, Naito S, Kawaese H, Muto A, et al. Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma. Br J Cancer. 2009;101(12):2005–14.
21. Tsukigi M, Bilim V, Yuuki K, Ugoikov A, Naito S, Nagaoka A, et al. Re-expression of miR-199a suppresses renal cancer cell proliferation and survival by targeting GSK-3beta. Cancer Lett. 2012;315(2):189–97.
22. Kawaese H, Bilim VN, Ugoikov AV, Yuuki K, Naito S, Nagaoka A, et al. GSK-3 inhibition in vitro and in vivo enhances antitumor effect of sorafenib in renal cell carcinoma (RCC). Biochem Biophys Res Commun. 2012;423(3):490–5.
23. Shinojima T, Oya M, Takayama Y, Mizuho R, Shimizu N, Murai M. Renal cancer cells lacking hypoosial inducible factor (HIF)-alpha expression maintain vascular endothelial growth factor expression through HIF-2alpha. Carcinogenesis. 2007;28(3):529–36.
24. Kocheva J. Blockage of autonomous growth of ACHN cells by anti-renal cell carcinoma monoclonal antibody 5F4. Cancer Res. 1990;50(10):2968–72.
25. Holland WS, Tepper CG, Pietri JE, Chinn DC, Gandara DR, Mack PC, et al. Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy. Cancer Chemother Pharmacol. 2012;69(1):165–84.
26. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58(3):621–81.
27. Bhat R, Xue Y, Berg S, Hellberg S, Ormo M, Nilsson Y, et al. Structural insights and biological effects of glycogen synthase kinase-3-specific inhibitor AR-A014418. J Biol Chem. 2003;278(45):45937–45.
28. Coghlan MP, Culbert AA, Cross DA, Corcoran SL, Yates JW, Pearce NJ, et al. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem Biol. 2000;7(10):793–803.
29. Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, Zhang X, et al. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell. 2006;126(5):955–68.

30. Shin S, Wolgammott L, Yu Y, Blenis J, Yoon SO. Glycogen synthase kinase (GSK)-3 promotes p70 ribosomal protein S6 kinase (p70S6K) activity and cell proliferation. Proc Natl Acad Sci U S A. 2011;108(47):E1204–13.

31. Shin S, Wolgammott L, Tcherkezian J, Vallabhapurapu S, Yu Y, Roux PP, et al. Glycogen synthase kinase-3beta positively regulates protein synthesis and cell proliferation through the regulation of translation initiation factor 4E-binding protein 1. Oncogene. 2014;33(13):1690–9.

32. McCubrey JA, Davis NM, Abrams SL, Montalto G, Cervello M, Basecke J, et al. Diverse roles of GSK-3: tumor promoter-tumor suppressor, target in cancer therapy. Adv Biol Regul. 2014;54:176–96.

33. Pause A, Belsham GJ, Gingras AC, Donze O, Lin TA, Lawrence Jr JC, et al. Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5′-cap function. Nature. 1994;371(6500):762–7.

34. Populo H, Lopes JM, Soares P. The mTOR signalling pathway in human cancer. Int J Mol Sci. 2012;13(2):1886–918.

35. Petroulakis E, Mamane Y, Le Bacquier O, Shahbazian D, Sonenberg N. mTOR signaling: implications for cancer and anticancer therapy. Br J Cancer. 2006;94(2):195–9.

36. Choi AR, Kim JH, Yoon S. Sensitization of cancer cells through reduction of total Akt and downregulation of salinomycin-induced pAkt, pGSK3beta, pTSC2, and p4EBP1 by cotreatment with MK-2206. BioMed Res Int. 2014;2014:295760.

37. Nagao T, Kurosu T, Umezawa Y, Nogami A, Oshikawa G, Tohda S, et al. Proliferation and survival signaling from both Jak2-V617F and Lyn involving GSK3 and mTOR/p70S6K/4EBP1 in PVT1-1 cell line newly established from acute myeloid leukemia transformed from polycythemia vera. PloS One. 2014;9(11):e84746.

38. Vinayagam A, Stelzl U, Fouille R, Plassmann S, Zenkner M, Timm J, et al. A directed protein interaction network for investigating intracellular signal transduction. Sci Signal. 2011;4(189):rs8.

39. Harth SE, Sadoshima J. Glycogen synthase kinase-3beta: a novel regulator of cardiac hypertrophy and development. Circ Res. 2002;90(10):1055–63.

40. The UniProt databases. http://www.uniprot.org/uniprot/Q13541#sequences. Accessed 16 May 2016.

41. Sutherland C. What are the bona fide GSK3 substrates? Int J Alzheimers Dis. 2011;2011:505607.

42. Chen CH, Shaikenov T, Peterson TR, Anibetov R, Bissenbaev AK, Lee SW, et al. ER stress inhibits mTORC2 and Akt signaling through GSK3-beta-mediated phosphorylation of rictor. Sci Signal. 2011;4(161):ra10.

43. Dibble CC, Asara JM, Manning BD. Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1. Mol Cell Biol. 2009;29(21):5657–70.